A clinical trial has found that treatment with the immunomodulator interferon beta-1a plus the antiviral remdesivir was not superior to treatment with remdesivir alone in hospitalized adults with COVID-19 pneumonia. In addition, in a subgroup of patients who required high-flow oxygen, investigators found that interferon beta-1a was associated with more adverse events and worse outcomes.
from Top Health News -- ScienceDaily https://ift.tt/3G1lV36
Subscribe to:
Post Comments (Atom)
-
Researchers from MIT and Scripps have unveiled a promising new HIV vaccine approach that generates a powerful immune response with just one ...
-
Three treaties between the US and Hong Kong were suspended, the latest move to pressure China. from Yahoo News - Latest News & Headl...
-
At least 22 people were killed and 171 others injured on Sunday when one of Taiwan’s newer, faster trains derailed on a curve along a popula...
No comments:
Post a Comment